A double-blind, randomized trial of sertraline for alcohol dependence: Moderation by age and 5-hydroxytryptamine transporter-linked promoter region genotype

Journal of Clinical Psychopharmacology

Volumn 31, Issue 1, 2011, Pages 22-30

  Kranzler, Henry R ^a,b   Armeli, Stephen ^c   Tennen, Howard ^b   Covault, Jonathan ^a   Feinn, Richard ^a   Arias, Albert J ^a   Pettinati, Helen ^d   Oncken, Cheryl ^b  

^a Alcohol Research Center   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 HTTLPR; age of onset; alcohol dependence; pharmacogenetics; SSRI; treatment response

Indexed keywords

PLACEBO; SEROTONIN TRANSPORTER; SERTRALINE;

ADULT; AGE; AGED; AGITATION; ALCOHOLISM; ALLELE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HOMOZYGOTE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ONSET AGE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE;

ADULT; AGE FACTORS; ALCOHOLISM; DOUBLE-BLIND METHOD; FEMALE; GENETIC LINKAGE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SERTRALINE;

EID: 78651340390     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31820465fa     Document Type: Article

References (53)

1. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: Findings of animal studies. Biol Psychiatry. 1994;36(6):395-421.
2. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: Clinical evidence. Biol Psychiatry. 1994;36(5):326-337. (Pubitemid 24288762)
3. Kranzler HR. Pharmacotherapy of alcoholism: Gaps in knowledge and opportunities for research. Alcohol Alcohol. 2000;35(6): 537-547.
4. Naranjo CA, Kadlec KE, Sanhueza P, et al. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther. 1990;47(4):490-498.
5. Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152(3):391-397.
6. Babor TF, Hofmann M, DelBoca FK, et al. Types of alcoholics. I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992;49(8): 599-608.
7. Kranzler HR, Burleson JA, Brown J, et al. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20(9): 1534-1541.
8. Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: Interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24(7):1041-1049.
9. Chick J, Aschauer H, Hornik K. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: A one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend. 2004;74(1):61-70.
10. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000;284(8):963-971.
11. Kranzler HR, Pierucci-Lagha A, Feinn R, et al. Effects of ondansetron in early- versus late-onset alcoholics: A prospective, open-label study. Alcohol Clin Exp Res. 2003;27(7):1150-1155.
12. Buydens-Branchey L, Branchey MH, Noumair D. Age of alcoholism onset. I. Relationship to psychopathology. Arch Gen Psychiatry. 1989;46(3):225-230.
13. Buydens-Branchey L, Branchey MH, Noumair D, et al. Age of alcoholism onset. II. Relationship to susceptibility to serotonin precursor availability. Arch Gen Psychiatry. 1989;46(3):231-236.
14. Swann AC, Johnson BA, Cloninger CR, et al. Relationships of plasma tryptophan availability to course of illness and clinical features of alcoholism: A preliminary study. Psychopharmacology (Berl). 1999;143(4):380-384.
15. Fils-Aime ML, Eckardt MJ, George DT, et al. Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics. Arch Gen Psychiatry. 1996;53(3):211-216.
16. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12(3):247-257.
17. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527-1531.
18. Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996;66:2621-2624.
19. Praschak-Rieder N, Kennedy J, Wilson AA, et al. Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: A [(11)C] DASB positron emission tomography study. Biol Psychiatry. 2007;62(4):327-331.
20. Greenberg BD, Tolliver TJ, Huang SJ, et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet. 1999;88(1):83-87.
21. Murphy DL, Lerner A, Rudnick G, et al. Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Mol Interv. 2004;4(2):109-123.
22. Hu XZ, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78(5):815-826.
23. Pierucci-Lagha A, Feinn R, Modesto-Lowe V, et al. Effects of rapid tryptophan depletion on mood and urge to drink in patients with co-morbid major depression and alcohol dependence. Psychopharmacology (Berl). 2004;171(3):340-348.
24. Moreno FA, Rowe DC, Kaiser B, et al. Association between a serotonin transporter promoter region polymorphism and mood response during tryptophan depletion. Mol Psychiatry. 2002;7(2):213-216.
25. Roache JD, Wang Y, Ait-Daoud N, et al. Prediction of serotonergic treatment efficacy using age of onset and type A/B typologies of alcoholism. Alcohol Clin Exp Res. 2008;32(8):1502-1512.
26. First M, Spitzer R, Gibbon M. Structured Clinical Interview for DSM-IC-TR Axis I Disorders, Research Version, Patient Edition with Psychotic Screen (SCID-I/P W/ PSYSCREEN). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2001.
27. Sobell L, Sobell M. Timeline follow-back: A technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring Alcohol Consumption. Clifton, NJ: Humana Press; 1992:41-72.
28. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
29. Kranzler HR, Abu-Hasaballah K, Tennen H, et al. Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study. Alcohol Clin Exp Res. 2004;28(7):1060-1064.
30. Feinn R, Tennen H, Cramer J, et al. Measurement and prediction of medication compliance in problem drinkers. Alcohol Clin Exp Res. 2003;27(8):1286-1292.
31. Miller W, Tonigan J. The Drinker Inventory of Consequences (DrInC). NIAAA Project MATCH Monograph Series, Vol. 4. NIH Publ. No. 95-3911. Bethesda, MD: National Institutes of Health 1995.
32. Feinn R, Tennen H, Kranzler HR. Psychometric properties of the short index of problems as a measure of recent alcohol-related problems. Alcohol Clin Exp Res. 2003;27(9):1436-1441.
33. Wei L. An application of an urn model to the design of sequential controlled clinical trials. J Am Statistic Assoc. 1978;73:559-563.
34. McCrady B, Dean L, DuBreuil R, et al. In: Marlatt GA, Gordon JR. Relapse Prevention. New York: Guilford Press; 1985.
35. Monti P, Abrams D, Kadden R, et al. Treating Alcohol Dependence: A Coping Skills Training Guide. New York: Guilford Press; 1989.
36. Hu X, Oroszi G, Chun J, et al. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res. 2005;29(1):8-16.
37. Nakamura M, Ueno S, Sano A, et al. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry. 2000;5(1):32-38.
38. Covault J, Tennen H, Herman AI, et al. Interactive effects of the serotonin transporter 5-HTTLPR polymorphism and stressful life events on college student drinking and drug use. Biol Psychiatry. 2007;61:609-616.
39. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA. 1988;85(14): 5274-5278.
40. Koob GF. Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci. 1992;13(5):177-184.
41. Fadda F, Garau B, Marchei F, et al. MDL 72222, a selective 5-HT3 receptor antagonist, suppresses voluntary ethanol consumption in alcohol-preferring rats. Alcohol Alcohol. 1991;26(2):107-110.
42. Wozniak KM, Pert A, Linnoila M. Antagonism of 5-HT3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol. 1990;187(2):287-289.
43. Yoshimoto K, Yayama K, Sorimachi Y, et al. Possibility of 5-HT3 receptor involvement in alcohol dependence: A microdialysis study of nucleus accumbens dopamine and serotonin release in rats with chronic alcohol consumption. Alcohol Clin Exp Res. 1996;20(Suppl 9):311AY319A.
44. Hodge CW, Samson HH, Lewis RS, et al. Specific decreases in ethanol- but not water-reinforced responding produced by the 5-HT3 antagonist ICS 205-930. Alcohol. 1993;10(3):191-196.
45. Dyr W, Kostowski W. Evidence that the amygdala is involved in the inhibitory effects of 5-HT3 receptor antagonists on alcohol drinking in rats. Alcohol. 1995;12(4):387-391.
46. Tomkins DM, Le AD, Sellers EM. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology (Berl). 1995;117(4):479-485.
47. Knapp DJ, Pohorecky LA. Zacopride, a 5-HT3 receptor antagonist, reduces voluntary ethanol consumption in rats. Pharmacol Biochem Behav. 1992;41(4):847-850.
48. Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18(4):879-885.
49. Roy A, Hu XZ, Janal MN, et al. Interaction between childhood trauma and serotonin transporter gene variation in suicide. Neuropsychopharmacology. 2007;32(9):2046-2052.
50. Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007;64(7):783-792.
51. Grant BF, Dawson DA, Stinson FS, et al. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend. 2004;74(3):223-234.
52. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry. 2009;66(8):848-856.
53. Mojtabai R, Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: Results from the national comorbidity survey replication. J Clin Psychiatry. 2008;69(7):1064-1074.